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Abstract
CD36 facilitates oxidized low density lipoprotein uptake and is implicated in development of atherosclerotic lesions. CD36
also binds unmodified high and very low density lipoproteins (HDL, VLDL) but its role in the metabolism of these particles is
unclear. Several polymorphisms in the CD36 gene were recently shown to associate with serum HDL cholesterol. To gain
insight into potential mechanisms for these associations we examined HDL metabolism in CD36 null (CD362/2) mice.
Feeding CD362/2 mice a high cholesterol diet significantly increased serum HDL, cholesterol and phospholipids, as
compared to wild type mice. HDL apolipoproteins apoA-I and apoA-IV were increased and shifted to higher density HDL
fractions suggesting altered particle maturation. Clearance of dual-labeled HDL was unchanged in CD362/2 mice and
cholesterol uptake from HDL or LDL by isolated CD362/2 hepatocytes was unaltered. However, CD362/2 hepatocytes had
higher cholesterol and phospholipid efflux rates. In addition, expression and secretion of apoA-I and apoA-IV were increased
reflecting enhanced PXR. Similar to hepatocytes, cholesterol and phospholipid efflux were enhanced in CD362/2
macrophages without changes in protein levels of ABCA1, ABCG1 or SR-B1. However, biotinylation assays showed increased
surface ABCA1 localization in CD362/2 cells. In conclusion, CD36 influences reverse cholesterol transport and hepatic ApoA-I
production. Both pathways are enhanced in CD36 deficiency, increasing HDL concentrations, which suggests the potential
benefit of CD36 inhibition.
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plasma cholesterol and HDL are modestly elevated (about
30%)[11], but the significance of this observation is unclear.
HDL level is influenced by that of very low density lipoproteins
(VLDL) and an inverse relationship is often observed between
serum levels of both lipoproteins[12]. High VLDL as a result of
increased hepatic secretion[12] or diminished clearance due to
lipoprotein lipase deficiency[13] usually associate with low HDL.
A major phenotypic characteristic of CD362/2 mice is a defect in
tissue FA uptake that feedbacks to inhibit VLDL clearance[14,15].
However, the expected inverse relationship between VLDL and
HDL does not hold in the CD362/2 mouse where both
lipoproteins were reported to be increased[11]. Recent evidence
suggested the possibility that CD36 may play a direct role in
HDL metabolism. A region of chromosome 7 (7q11.2–7q21.11)
encompassing the CD36 gene was linked to components of the
metabolic syndrome including HDL in genome-wide linkage
studies[16]. Our study in a large population sample identified
strong associations between single nucleotide polymorphisms
(SNPs) in the CD36 gene and serum HDL cholesterol[17]. Of
thirty-six CD36 tag SNPs that were examined, nine associated
with increased serum HDL-C and seven with reduced HDL-C.
These associations remained significant after adjusting for
triglyceride (TG) levels consistent with a direct effect. These

Introduction
Cluster of Differentiation 36 (CD36) is an 88 kD transmembrane glycoprotein and type B scavenger receptor with a range of
lipid ligands that includes long chain fatty acids (FA)[1] and native
or modified lipoproteins[2]. As a result, CD36 is implicated in
various cellular activities linked to a number of pathologies
including atherosclerosis[3]. Cholesterol uptake by macrophages
from oxidized low density lipoproteins (ox-LDL) or LDL promotes
formation of lipid-laden ‘‘foam’’ cells, a critical step in atherosclerotic lesion formation. CD36 facilitates ox-LDL uptake by binding
the modified lipids and internalizing the particles [4]. CD36 was
also shown to delay degradation of native LDL in vivo[5]. These
two functions would be predicted to have a pro-atherosclerotic
effect.
High density lipoproteins (HDL) have an antiatherogenic effect
reflecting their function in reverse cholesterol transport to the liver
and their anti-oxidant properties[6]. Like SR-B1, a family member
and HDL receptor[7], CD36 binds these particles with high
affinity[8,9]. However, its efficiency in mediating selective
cholesteryl ester (CE) uptake is low compared to SR-B1[9,10],
which led to the concept that it has a minor if any role in HDL
metabolism. In CD36 null (CD362/2) mice fed a chow diet,
PLoS ONE | www.plosone.org
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observations suggested that the role of CD36 in HDL metabolism
may be underappreciated.
In this report we describe the impact of CD36 deficiency in
mice on HDL metabolism and examine the mechanisms involved.
Our results implicate CD36 in reverse cholesterol transport and in
hepatic secretion of HDL apolipoproteins, two processes that
influence HDL levels.

In vivo HDL clearance
Anesthetized mice (5 females and 10 males per genotype) were
injected 0.2-ml of labeled hHDL3 (,180 mg hHDL3 protein,
1.7 mCi 125I and 0.5 mCi 3H) via the external jugular vein [22,23].
Venous blood was collected from the retro-orbital plexus in
heparin-coated capillaries (,50 ml) at 1, 5, 10, 20, 30 40, 60, 90,
120, 180, and 240 minutes later. Radioactivity (3H and 125I) was
counted in plasma and normalized to HDL concentration. Data
are expressed as percent of levels at 1 min after injection.

Materials and Methods
Animals and diets

In vitro HDL and LDL uptake by primary hepatocytes

CD362/2 mice[11] on the C57BL/6J genetic background were
housed in a barrier facility with free access to food and water. For
the high cholesterol feeding studies, 8 week-old mice were
maintained on a high fat, high cholesterol (HFHC) diet (Teklad
Harlan, TD.02028, 42% calories from fat, 1.25% cholesterol) for 4
weeks. For studies with isolated hepatocytes and macrophages and
in vivo HDL clearance 12 week-old mice fed CHOW were used. All
experimental protocols were performed in compliance with the
standards established by the US Animal Welfare Acts, and were
approved by the Animal Study Committee of Washington
University School of Medicine.

Mouse hepatocytes were isolated [24] and maintained in
DMEM with 10% FBS. For HDL assays, dual-labeled HDL3
were added to the media (0.1, 0.2, and 0.3 mg/ml HDL3) for 3 hr.
The medium was then removed and the cells washed with PBS
before lysis in 0.2N NaOH for radioactivity counts, later adjusted
for protein content. For LDL assays, hepatocytes were incubated
with 3H-cholesteryl oleolyl labeled hLDL (0.1 mg/ml) for 5 hr
before processing as for HDL uptake.

ApoA-I and apoA-IV synthesis and secretion by primary
hepatocytes

Plasma lipid measurements

Synthesis and secretion of apoA-I and apoA-IV by primary
hepatocytes were determined using 35S labeled methionine and
cysteine[25]. Freshly isolated hepatocytes were incubated in
methionine and cysteine-free DMEM (Sigma Aldrich, St. Louis,
MO) for 30 minute then switched to the same medium but with
5 mCi/ml 35S labeled Met and Cys (Easytag Protein Labeling mix,
Perkin Elmer, Waltham, MA) for 3 hr. Medium and cells were
harvested, and immunoprecipitated again apoA-I, apoA-IV, and
albumin antibodies. Proteins were separated by SDS-PAGE, fixed,
dried, and exposed against X-ray film. Albumin abundance was
used as an internal standard.

Plasma lipids were measured using 12 hours fasted mice. Blood
samples, 50 ml, were collected from the mouse tail vein in heparin
coated capillaries, and plasma was obtained by centrifugation at
12,000 g for 5 minutes at 4uC. Plasma triglyceride (TG), total
cholesterol (CHOL), HDL-cholesterol, phospholipids (PL), and
free fatty acids (FA) were measured using enzymatic kits (Wako
Chemicals, Richmond, VA).
Lipoprotein fractionation was conducted by fast protein liquid
chromatography (FPLC) using a Superose 6 column HR13/50
and pooled plasma from 4 mice (5–6 hr after food removal in the
morning). A total of 45–0.5 ml samples were collected from each
fractionation. Cholesterol concentration was measured as described above, and lipoprotein apoA-I and apoA-IV distribution
was determined by Western blot analysis as described below.

Cholesterol and phospholipid efflux assays in primary
hepatocytes and macrophages
Mice were intraperitoneally injected with 2 ml of 4.5%
thioglycollate 4 days before harvesting peritoneal macrophages
by lavage[26]. The macrophages were incubated overnight in 12well plates (0.56106 cells/well) in RPMI-1640 supplemented with
10% FBS and antibiotics.
Cholesterol and phospholipid efflux assays were as described
[20,27]. For cholesterol efflux, the cells were loaded with
cholesterol for 18 hr in DMEM (hepatocyte) or RPMI-1640
(macrophage) with 0.2% FA-free BSA, labeled LDL or ac-LDL
(1 mCi/well) and ACAT inhibitor (10 nM oleic acid-2,6-diisopropylanilide, Cayman Chemical Co., Ann Arbor, MI). The next day,
the cells were washed twice with pre-warmed PBS and incubated
in fresh DMEM- or RPMI-0.2% BSA for 15 min before switching
to medium containing isolated hHDL2 or purified human apoA-I
(A0722, Sigma-Aldrich, St. Louis, MO) at the indicated
concentrations for a 12 hr efflux assay. Media were collected
and cleared from cell debris by centrifugation. Cells were washed
and scrapped in cold PBS with proteinase inhibitor (SigmaAldrich, St. Louis, MO). For phospholipid efflux assays, cellular
phospholipids were labeled by incubating the cells with 0.5 mCi
[3H]-choline (American Radiolabeled Chemicals, St. Louis, MO)
in DMEM or RPMI-10% FBS for 24 hr. After washing the cells
were incubated in serum-free medium with hHDL2 for 12 hr.
Media and cells were then extracted for lipids (chloroform/
methanol, 1:1, v/v). Lipid radioactivity was counted and adjusted
for cellular protein content.

Lipoprotein isolation and labeling
Plasma from human donors was subjected to serial gradient
ultracentrifugation as described[18]. LDL was isolated from the
density range 1.019 to 1.063 g/ml, HDL2 from 1.063–1.125 g/ml
and HDL3 from 1.125–1.210 g/ml. Isolated lipoproteins were
dialyzed against 4 L of 0.8% saline-EDTA overnight at 4uC under
nitrogen gas. Protein concentration was determined using the
BCA assay (Bio-Rad, Hercules, CA).
Acetylated-LDL (ac-LDL) were prepared and labeled as
described[19]. Briefly, LDL isolated from human plasma (0.5–
1.0 mg protein/ml) was diluted 1:1 with saturated sodium acetate
while continuously stirred on ice. Acetic anhydride was added with
stirring in aliquots (2 ml) and up to 1.5 times the protein mass
(1.5 ml/mg). The mixture was stirred for 30 more min then
dialyzed (24–36 h, 4uC) against 2 liters of buffer (0.15 M NaCl,
0.3 mM EDTA, pH 7.4) with 6 changes (total 12 L). Protein
content was determined after dialysis. LDL or ac-LDL (1 ml,
0.5 mg protein) were labelled [20] either with 3H-cholesterololeate (50 mCi, Perkin Elmer Life Sciences) or 14C-cholesterol
(50 mCi, American Radiolabeled Chemicals, St. Louis, MO).
For HDL clearance assay, human HDL3 were dual labeled with
125
I-dilactitol tyramine and 3H-cholesteryl oleolyl ether [9,21].
The 125I/3H-hHDL3 was dialyzed against buffer (0.15 M NaCl,
0.3 mM EDTA) to remove free label. Specific activity was
20.860.1 (125I) and 6.460.3 (3H) dpm/ng protein.
PLoS ONE | www.plosone.org
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Biotin labeling of cell membrane proteins

Table 1. Serum phospholipids and cholesterol in WT and
CD36null mice fed chow or high fat high cholesterol diets for
4 weeks.

For biotin labeling of surface proteins[28] cells were incubated
in PBS (with 0.1 mM Ca2+, 0.5 mM Mg2+) with 500 mg/ml sulfosuccinimido-biotin (Pierce-Thermo Scientific, Waltham, MA) for
30 min at 4uC. The washed cells were lysed (50 mM Tris, 1 mM
EDTA, 1%Triton, 2%SDS, 1X proteinase inhibitor, pH = 7.4)
and about 10% of lysates was saved for protein assays. The rest
was used for immunoprecipitation of biotin-labeled proteins using
streptavidin-magnetic beads (2 hrs, 4uC). Biotin-labeled proteins
were separated by SDS-PAGE alongside total cell proteins.
Antibodies for Cadherin 1(CDH1, Abcam, Cambridge, MA) was
used as a cell membrane marker.

Gender

WT

CD362/2

P value

CHOW
Chol (mg/dL)

PL (mg/dL)

F

83.067.4

132.3618.2

0.001

M

83.267.0

111.5615.7

0.003

F

62.667.5

135.367.7

,0.001

M

95.367.8

73.3632.8

0.196

HFHC

RT-PCR

Chol (mg/dL)

Total liver RNA was isolated using Trizol (Invitrogen, Carlsbad,
CA) and further purified by RNeasy columns (Qiagen Sciences,
Valencia, CA). cDNA was synthesized using high capacity cDNA
reverse transcription kit (Applied biosystems, Foster City, CA) and
changes in transcript abundance were measured using SYBRgreen PCR Master kit on a ABI-7500 real-time PCR system. For
each genotype, mRNA from 8 mice was randomly combined
to form 2 pools of equal concentration. Each primer pair was
repeated 3 times on a 96-wells plate (6 measurements per
genotype) and duplicate plates were used. The 36B4 gene was
used as a normalization standard. The RT-PCR primer sequences
and relevant references were listed in Table S1.

PL (mg/dL)

128.4631.1

194.7623.3

,0.001

M

138.6651.2

236.8656.8

,0.001

F

87.0618.2

185.5622

,0.001

M

126.9632.4

186.0642.9

0.035

1. Parameters are from 12-week old mice after an overnight fast, n = 8
per genotype.
2. P value is for differences between WT and CD362/2 mice.
3. Chol, cholesterol; PL, phospholipids.
doi:10.1371/journal.pone.0009906.t001

sex. The increased serum cholesterol was primarily localized to
HDL subfractions as shown in Figure 1(A and B). Consistent with
the higher HDL concentrations, plasma levels of HDL constituent
apolipoproteins, apoA-I and apoA-IV, were also higher in
CD362/2mice (Figure 1C). On the other hand, levels of apoB48
and apoE (components of chylomicrons and VLDL) were similar.
Figure 1C also shows that the apolipoprotein profile was not
altered by the diet except for a HFHC-induced increase in apoE
levels. These data showed that CD362/2 mice exhibit higher
levels of plasma cholesterol than WT mice and this difference is
exaggerated upon feeding a cholesterol rich diet. The higher HDL
levels were present in male and female mice and were not altered
by the nutritional state of the mice; HDL levels, in fed versus 6 and
14 hr fasted mice were reproducibly higher in CD362/2 as
compared to WT mice (data not shown).
We next examined whether there were changes in apolipoprotein content of HDL subfractions collected from FPLC. As
shown in Figure 1D and E, apoA-I and apoA-IV distribution in
CD362/2 samples shifted to higher density fractions (more
apparent in female mice) suggesting presence of more lipid poor
HDL particles.

Western Blots
Proteins separated by SDS-PAGE were transferred to a PVDF
membrane (Millipore, St. Charles, MO) and probed with
antibodies. Polyclonal antibodies against mouse apoB, apoA-I,
apoA-IV, and apoE were generated and used as reported[24].
Rabbit polyclonal antibody against mouse SR-B1 (Novus
Biologicals, Litteton, CO), mouse monoclonal antibodies against
ABCA1, ABCG1, CDH1(Abcam, Cambridge, MA), PPARc and
b-Actin (Santa Cruz Biotech, CA) were used as recommended by
the manufacturers. Immune signals were detected and quantified
using LI-COR Odyssey Imaging (Lincoln, NE) with near-infrared
dye labeled secondary antibodies except for 35S labeling of hepatic
apolipoprotein synthesis and secretion where X-ray film was used.

Statistical Analysis
Statistical analyses used SAS (9.02 Cary, NC). Differences were
considered significant if the p-value was less than 0.05.

Results

In vivo HDL clearance

HDL levels and distribution in CD362/2 and WT mice fed
a high cholesterol diet

A major regulator of plasma HDL levels is HDL clearance by
hepatocyte-mediated selective CE uptake[30]. Adenoviral overexpression of CD36 in the liver was previously found not to alter
plasma HDL[10]. We examined whether CD36 deletion, which
alters plasma HDL, impacts HDL clearance by reducing hepatic
CE uptake[9]. CD36 deficiency could also impact the process
indirectly through altered activation of peroxisome proliferatoractivated receptors (PPARs)[31] which modulate several aspects of
lipoprotein metabolism[32]. We quantified in vivo HDL catabolism
using 125I (apolipoprotein) and 3H-cholesteryl oleolyl ether duallabeled human HDL3. Each mouse was injected with 200 ml of
labeled lipoprotein and plasma radioactivity was measured
over 2 hrs. Counts were adjusted for the higher HDL levels in
CD362/2 mice. As shown in Figure 2, there was no difference in
HDL-CE clearance rate between genotypes (Fig. 2A) and
clearance of 125I-HDL apolipoprotein was also similar (Fig. 2B).

The initial report on CD36 deficient mice fed a chow diet with
4% fat described a modest increase (30%) of plasma cholesterol
and HDL as compared to WT mice[11] but increased HDL were
not noted in other studies[5,29]. As shown in Table 1, we
confirmed observations[11] of significantly higher plasma cholesterol in CD362/2 as compared to WT mice maintained on chow
and the difference was observed in both males and females.
Phospholipid (PL) levels were also increased in female but not in
male CD362/2 mice. To further validate the differences in HDL
levels between the genotypes, the mice were challenged with a
high fat, high cholesterol (HFHC) diet for 4 weeks. The HFHC
diet significantly increased blood cholesterol and PL (Table 1) in
all mice. However, levels of both lipids were significantly higher
(1.5–2 fold) in CD362/2, as compared to WT mice, regardless of
PLoS ONE | www.plosone.org
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Figure 1. Effect of a cholesterol rich diet on plasma cholesterol and apolipoprotein content of HDL subfractions in WT and CD36
null (CD362/2) mice. Pooled plasma (4–5 mice per genotype) collected in the postprandial state (5–6 hrs after food removal) was used for
fractionation. Panels A and B: Cholesterol content of FPLC fractions, WT (solid line), CD362/2 (dashed line), female (A), male (B). Panel C: Western
blot of plasma apolipoproteins from mice fed CHOW or high fat high cholesterol (HFHC). Panels D and E: Expanded graphs showing cholesterol in
HDL subfractions 26–42 and the corresponding apolipoprotein distribution. HDL fractions were separated by SDS-PAGE and blotted against
polyclonal antibodies for apoA-I and apoA-IV. Data are representative of two fractionation assays per experiment from two separate experiments.
doi:10.1371/journal.pone.0009906.g001

This suggested that HDL clearance does not contribute to
elevating plasma HDL in CD362/2 mice.

Efflux of cholesterol and phospholipids from primary
hepatocytes
The possibility that there was alteration of cholesterol efflux by
the CD362/2 liver was tested next. Cholesterol efflux from
hepatocytes can influence plasma HDL concentrations. In
addition efflux of cholesterol especially that mediated by the
ABCA1 transporter is coupled to that of phospholipids[6]. As
shown earlier in Table 1, differences in both plasma cholesterol
and phospholipid levels were measured in CD362/2 as compared
to WT mice. We examined efflux efficiency of these lipids by
primary hepatocytes isolated from both mice groups. Freshly
isolated hepatocytes were first loaded with 14C-cholesterol or with
3
H-choline chloride (to label cell phospholipids). Cells were then
allowed to efflux 14C-cholesterol or 3H-phosphotidylcholine to
HDL3 0.1 mg/ml overnight. Surprisingly, as shown in Figure 3A
and B, CD362/2 hepatocytes had significantly higher cholesterol
and phospholipid efflux efficiency. At the end of the incubation
with HDL3, about 30% of labeled cholesterol effluxed into the
medium in WT hepatocytes as compared to 50% for CD362/2
cells (Fig. 3A). CD362/2 cells also effluxed a higher proportion of

HDL and LDL uptake by isolated hepatocytes
To further validate the interpretation that hepatic HDL
clearance is not altered in CD362/2 mice, we compared directly
in vitro selective CE uptake by primary hepatocytes isolated from
WT and CD362/2 mice. The cells were incubated with different
concentrations (0.1, 0.2, and 0.3 mg/ml) of [3H]-cholesteryl
oleolyl ether labeled hHDL3 for 3 hrs. Selective cholesterol uptake
showed an almost linear response to hHDL3 loading and was
similar for cells from WT and CD362/2 mice as shown in
Figure 2C.
Cholesteryl ester in HDL can be transferred to apoB-containing
lipoproteins and taken up by the liver via the LDL receptor[33].
The possibility that this pathway is enhanced in CD362/2
hepatocytes was tested using 3H-cholesterol oleate labeled hLDL
and as shown in Figure 2D, no genotype related difference was
observed. The above data indicated that hepatocyte handling of
CE from HDL or LDL was unaltered by CD36 deficiency.
PLoS ONE | www.plosone.org
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Figure 2. HDL clearance in vivo and cholesterol uptake by isolated hepatocytes in vitro. Panels A and B: In vivo HDL clearance. 200 ml of
[3H]- and [125I]-dual labeled human HDL was injected into the mouse tail vein and plasma radioactivity (panel A: [3H] and panel B: [125I]) was
measured at the times indicated. Five females and 10 males were used per genotype. Panels C and D: In vitro cholesterol uptake. Hepatocytes
isolated from WT and CD362/2 mice, were plated at a density of 0.56106 cells/well and assayed for cholesterol uptake, using either HDL or LDL.
Panel C: Cholesterol uptake from HDL using three concentrations of 3H-cholesteryl oleolyl ether labeled human HDL3 for 3 hours. Panel D:
Cholesterol uptake from LDL with cells incubated with 3H-cholesteryl oleolyl labeled native hLDL for 5 hr. Data are means (n = 4) shown with standard
errors and representative of two separate experiments.
doi:10.1371/journal.pone.0009906.g002

cellular PL than WT cells (Fig. 3B). These data suggested that
CD36 may negatively influence hepatic cholesterol and phospholipid efflux so this is enhanced in CD36 deficiency.
Cholesterol and phospholipid efflux from hepatocytes is
primarily facilitated by the ATP cassette transporters ABCA1
and ABCG1[34] with a more minor role for SR-B1[35]. We
examined whether increased cholesterol efflux was due to
increases in these proteins. However, Western analysis using liver
homogenates showed no differences between genotypes (Fig. 3C).

(p = 0.011 and 0.002 for cellular and media apoA-I content
respectively). This suggested that enhanced production of HDL
apolipoproteins may contribute to the high HDL in CD362/2
mice.
To determine whether the increased synthesis of apoA-I and
apoA-IV in CD362/2 hepatocytes involved transcriptional or
post-translational mechanisms, we measured hepatic mRNA of
the corresponding genes. Levels of APOA-I and APOA-IV mRNA
were significantly higher in CD362/2 livers (Fig. 3E). Hepatic
expression of apoA-I and apoA-IV is regulated by many factors,
including pregnane X receptor (PXR) and hepatocyte nuclear
factor 4 (HNF4)[37]. RT-PCR showed that PXR expression in
CD362/2 liver was significantly increased while that of HFN4
and LXR was unaltered (Fig. 3F). PXR represses transcription of
genes involved in lipid b-oxidation, such as carnitine palmitoyl
transferase 1(CPT1) and 3-Hydroxy-3-Methylglutaryl CoA Reductase (HMGCR)[38]. Consistent with enhanced PXR expression,
hepatic CPT1b and HMGCR expression was significantly lower
in CD362/2 as compared to WT mice (Fig. 3E). Expression of
ABCA1 was slightly increased while that of ABCG1 was not
altered.

Synthesis and secretion of ApoA-I and IV by isolated
hepatocytes
Elevated HDL can result from over-production of apoA-I[36].
In addition as shown in Figure 1, CD362/2 mice had higher
plasma levels of HDL apolipoproteins, so we examined whether
CD36 deficiency alters hepatic apoA-I and apoA-IV production
and secretion. Hepatocytes from WT and CD362/2 mice were
labeled with 35S for 3 hr then cellular and medium apoA-I and
apoA-IV were immunoprecipitated using the respective antibodies. Figure 3D shows that apoA-I and apoA-IV synthesis and
secretion were increased in CD362/2 as compared to WT cells
PLoS ONE | www.plosone.org
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Figure 3. Hepatocytes from WT and CD362/2 mice. Cholesterol and phospholipid efflux, apoA-I production and expression of genes that
regulate cholesterol metabolism. Primary hepatocytes were isolated from WT and CD362/2 mice and assayed for cholesterol and phospholipid efflux.
Hepatocytes were loaded with 14C-cholesterol and 3H-choline chloride (to label cell phospholipids) as described in Methods. Cells were then allowed
to efflux 14C-cholesterol and 3H-phosphotidylcholine overnight. Panel A: cholesterol efflux and Panel B: phospholipid efflux for WT and CD362/2
hepatocytes. Data (DPM adjusted for cellular protein) are means (n = 4) shown with standard errors and typical of three experiments. Panel C:
Western blot showing expression of proteins related to cholesterol and phospholipid efflux. Data are representative of three separate experiments.
Panel D: ApoA-I production and secretion assayed in primary hepatocytes labeled with 35S. Data are from two separate experiments with 3
independent samples in each experiment. Relative band intensity (intensity of apoA-I/intensity of albumin band) was quantified using ImageJ
software (http://rsbweb.nih.gov/ij/). ApoA-I levels were significantly higher in CD362/2 as compared to WT hepatocytes (p = 0.011 and 0.002 for cell
and media respectively). ApoA-IV secretion was significantly higher in CD362/2 (p = 0.008), but not production (p.0.05). Panel E: Gene expression
measured by RT-PCR of transcriptional factors that regulate apoA-I expression and Panel F: of genes targeted by PXR. In both panel E and F, n = 6 on
each assay plate, and data are representative of three separate experiments.
doi:10.1371/journal.pone.0009906.g003

Overall, the findings indicated that CD362/2 mice have
increased hepatic apoA-I and apoA-IV synthesis and secretion
as well as enhanced hepatocyte cholesterol and phospholipid
efflux. Both changes would contribute to elevating plasma HDL in
CD36 deficiency.

in lipid extracts of cells and medium. Figure 5A shows that [3H]
incorporation into cellular PL was similar for WT and CD362/2
macrophages. However, as with cholesterol, CD362/2 macrophages showed enhanced PL efflux (Fig. 5B), and efflux efficiency
(Fig. 5C).
Cholesterol and phospholipid efflux from macrophage is
primarily facilitated by ABCA1 and to a lesser extent by
ABCG1[34] and SR-B1[35]. ABCA1 expression in macrophages
is stimulated by liver-X-receptors (LXRs) which in turn is
modulated by peroxisome proliferator-activated receptor gamma
(PPARc)[30]. We examined whether CD36 deficiency associates
with alterations in protein levels of PPARc, ABCA1, ABCG1 and
SR-B1. As Figure 6A shows, there were no noticeable differences
in the amount of these proteins between WT and CD362/2
macrophages. ABCA1 recycles between plasma membrane and
intracellular compartments and membrane transporter content
can be altered without changes in total ABCA1 protein[40]. We
determined whether CD36 deficiency alters ABCA1 membrane
content by biotin labeling of macrophage surface proteins. As
shown in Figure 6B, these assays documented a significant
increase of cell surface ABCA1 in CD362/2 as compared to
WT macrophages. In contrast, cell-surface SR-B1 was minimally
altered. When cell surface ABCA1 was adjusted by cell membrane marker Cadherin 1 (CDH1), membrane-bound ABCA1 in
CD362/2 cells was almost double that in WT cells (p = 0.03,
Figure 6C). These data suggested that CD36 increases cholesterol
efflux in macrophages at least in part by influencing cell
membrane ABCA1 distribution. A similar increase in surface
ABCA1 was observed in CD362/2 hepatocytes suggesting that
this interpretation may also apply to cholesterol efflux from these
cells (Figure S1). Although preparations of isolated hepatocytes are
largely pure as a result of the fact that hepatocytes are the major
cell type in the liver, he possibility that the increase in cholesterol
efflux from hepatocytes could reflect contaminating macrophages
was ruled out by assaying expression of the macrophage specific
marker F4/80. As shown in Figure S2, F4/80 levels in the
hepatocyte preparations were very low to undetectable.

Efflux of cholesterol and phospholipids from isolated
macrophages
A cell type that is central to cholesterol homeostasis is the
macrophage. Conversion of macrophages to lipid laden foam cells
as a result of excess cholesterol uptake or defective cholesterol
efflux is implicated in lesion development[6]. CD36 deficiency
reduces uptake of modified lipoproteins by macrophages limiting
foam cell formation[2]. We examined whether the deficiency
also influences macrophage cholesterol efflux similar to its effect
on hepatocytes. Intraperitoneal macrophages from WT and
CD362/2 mice were assayed for capacity to efflux CE to HDL.
In a first approach, macrophages were preloaded overnight with
[3H]-cholesterol oleate labeled ac-LDL (1.06106 dpm/mg protein). The washed cells were switched to serum-free RPMI
containing 0.1 mg/ml hHDL2 for 12 hrs and then cells and media
were collected for [3H] counts.
CD362/2 macrophages demonstrated the expected impairment
of ac-LDL cholesterol uptake[5] accumulating about 25% of
counts recovered in WT cells (Fig. 4A). However, despite the lower
level of cholesterol loaded into CD362/2 cells, a similar amount of
[3H]-cholesterol effluxed into the HDL containing medium
(Fig. 4B). Percent cholesterol efflux ([3H] in media/total [3H]
adjusted by protein content) for CD362/2 macrophages was
about 4–6% as compared to ,1% for WT cells (Fig. 4C). To
separate cholesterol uptake and efflux we equalized cellular
cholesterol loading before efflux initiation by incubating macrophages with unmodified LDL labeled with [14C]-cholesterol. LDL
uptake by macrophage is mediated by the LDL receptor[5,39]
independent of CD36 so [14C]-LDL loading resulted in similar
[14C]-cholesterol accumulation by WT and CD362/2 macrophages (p = 0.37, Fig. 4D). Again, as shown in Figure 4E, cells
from CD362/2 mice effluxed more [14C]-cholesterol into the
medium (p = 0.042), and had significantly higher efflux efficiency
(p = 0.049, Fig. 4F). Thus the enhanced cholesterol efflux of
CD362/2 cells was independent of cellular cholesterol.
Some studies suggested that cholesterol efflux mediated by
ABCA1 favors lipid-poor apoA-I instead of HDL particles[6]. We
also conducted efflux experiments using 50 mg/ml human apoA-I
as the lipid acceptor. As shown in Figure 4G–H, cells from
CD362/2 mice effluxed more cholesterol to media apoA-I
(p = 0.003, Figure 4H) and had higher efflux efficiency than WT
cells (p = 0.047, Figure 4I).
To examine PL efflux, macrophages were preincubated with
[3H]-choline (24 hrs), washed and switched to medium containing
0.2 mg/ml human HDL2 for 8 hrs. Radioactivity was determined
PLoS ONE | www.plosone.org

Discussion
There is strong evidence in rodent models and humans to
support a role of CD36 in uptake of FA and oxidized lipoproteins
and in mediating signal transduction in response to these
ligands[1,2]. CD36 is also a high affinity receptor for native
lipoproteins as reported in 1998[8]. However, its role in the
metabolism of these particles has been relatively little studied.
Recent work documented that CD36 can facilitate CE uptake
from native LDL and that it delays LDL clearance in vivo[5]. In the
case of HDL, CD36 binds these particles as well as SR-B1 but is
less efficient in mediating selective HDL-CE uptake and does not
promote whole particle endocytosis[9,10,41,42,43]. In vivo CD36
overexpression in the liver did not alter plasma HDL in mice so
7
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Figure 4. Cholesterol efflux in macrophages from WT and CD362/2 mice using different lipoprotein substrates. Macrophages isolated
from WT and CD362/2 mice were cholesterol loaded by preincubation (12 hr) with 3H-cholesterol oleate labeled ac-LDL (panels A, B and C) or 14Ccholesterol labeled native LDL (panels D, E, F, G, H, and I). For cholesterol efflux assays, the cells were switched to a serum-free medium containing
0.1 mg/ml human HDL2- for 8 hours. Media and cells were then collected and assayed for radioactivity. Panel A: Cholesterol uptake from ac-LDL by
CD36+/+ and CD362/2 macrophages. Panel B: Cholesterol efflux into HDL-containing medium. Panel C: Efflux efficiency, 3H-cholesterol oleate efflux
expressed as percent of cellular 3H at efflux initiation. Data are means (n = 4) shown with standard errors and are typical of three separate
experiments. Panel D to F: macrophage efflux assay using hHDL2 as efflux substrate. Panel D: [14C]-cholesterol uptake by macrophages preincubated
with native 14C-LDL (0.3 mg/ml). Panel E: Cholesterol efflux by 50 mg/ml HDL2 (DPM adjusted for cell protein). Panel F: Efflux efficiency (percent of
total 14C in the media adjusted by protein content). Data are means with standard errors (n = 4) typical of three separate experiments. Panel G to I:
macrophage efflux assay using human apoA-I as efflux substrate. Panel G: [14C]-cholesterol uptake by macrophages preincubated with native 14CLDL (0.3 mg/ml). Panel H: Cholesterol efflux by 50 mg/ml human apoA-I (DPM adjusted for cell protein). Panel I: Efflux efficiency (percent of total
14
C counts in the media adjusted by protein content). Data are means with standard errors (n = 4).
doi:10.1371/journal.pone.0009906.g004

HDL[17]. These findings, together with the earlier observation
of high cholesterol and HDL levels in CD36 knockout mice[11]
led us to consider a potential physiological role of CD36 in HDL
metabolism, which was explored in the present study. HDL

the functional relevance of the protein in HDL metabolism was
considered minimal[10]. Our recent family based association
study in a large African American population sample, identified a
surprising number of CD36 SNPs that influenced plasma
PLoS ONE | www.plosone.org
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CD36 null mice, regardless of sex, exhibited an exaggerated
response of plasma HDL to increased dietary supply of cholesterol.
HDL levels were substantially higher in CD362/2 mice and
parallel increases were measured in plasma phospholipids and
cholesterol. HDL clearance in mice is mainly accomplished via
selective CE uptake by the liver primarily via SR-B1 (reviewed in
[7,44]). Reduced activity of hepatic SR-B1 impedes HDL
clearance and increases serum HDL levels [45,46,47]. CD36
expression in the liver is relatively low but levels are up-regulated
under various conditions associated with steatosis[5,48]. The low
hepatic CD36 levels, the previous demonstration that CD36 is less
efficient than SR-B1 in selective HDL-CE uptake, and the finding
that hepatic CD36 overexpression in mice did not alter plasma
HDL levels[10] suggested that CD36 function in HDL clearance
may not be relevant physiologically[9,10]. Our findings using the
opposite condition of CD36 deletion also demonstrate that in vivo
the protein does not significantly contribute to HDL clearance.
Absence of CD36 did not alter kinetics of labeled HDL in vivo and
CD36 deficient hepatocytes assayed in vitro exhibited rates of HDL
uptake that were similar to CD36 sufficient hepatocytes. Thus
defective HDL clearance is not responsible for the elevated HDL
in CD362/2 mice or for the exaggerated response of plasma
cholesterol and phospholipids in these mice to the high cholesterol
diet.
The mechanisms underlying the effect of CD36 deficiency
on HDL levels involve a combination of increased hepatic
apoA production and enhanced cellular efflux of cholesterol
and phospholipids. ApoA-I is the major HDL apolipoprotein and
is mainly synthesized in the liver[37]. ApoA-I regulation is
transcriptional[37] or post-transcriptional[49]. ApoA-I expression

Figure 5. Phospholipid efflux in macrophages from WT and
CD362/2 mice. Panel A: Content of 3H-labeled phospholipids in
macrophages preincubated with 0.5 mCi/ml of [3H]-choline chloride for
24 hours. Panel B: PL efflux (DPM/cell protein) into serum-free RPMI with
hHDL2 for 8 hr. Panel C: Efflux efficiency. Data are means (n = 4) shown
with standard errors and are typical of three separate experiments.
doi:10.1371/journal.pone.0009906.g005

distribution and kinetics in CD362/2 mice and impact of CD36
deficiency on cholesterol uptake and efflux in primary hepatocytes
and macrophages were examined. The findings document that
CD36 influences plasma apoA-I, apoA-IV, cholesterol and
phospholipid levels. The mechanisms involved include increased
hepatic expression and synthesis of HDL apolipoproteins and
enhanced efflux of cholesterol and phospholipids by hepatocytes
and macrophages. The data demonstrate a novel role of CD36 in
the regulation of reverse cholesterol transport.

Figure 6. Total and cell surface proteins in primary macrophages from WT and CD362/2 mice. Panel A. Total protein content,
determined by western blot for macrophages isolated and pooled from 4–5 mice per genotype. Detection was by infrared secondary antibodies.
Panel B: Cell-surface proteins determined using biotin labeling as described in Methods (first row). CDH1 was used as a cell surface protein marker
(the second row). Total cellular ABCA1 for respective samples was listed in the third row. Panel C. Relative intensities of the macrophages surface
proteins ABCA1 between WT and CD362/2 mice. Intensity of protein bands (ABCA1) from 8 independent samples (4 WT and 4 CD362/2) were
quantified and expressed as a relative intensity of intensity of CDH1 in the same sample.
doi:10.1371/journal.pone.0009906.g006
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is influenced by PPARa, PXR and HNF4. The increase in apoA
synthesis in livers of CD362/2 deficient mice may reflect a PXRmediated increase in apoA-I gene transcription. Like apoA-I,
CD36 is a direct target of PXR[48] and the increased PXR
expression in the CD362/2 liver suggests a regulatory loop similar
to the one that exists between CD36 and PPARd[31].
The enhanced apoA supply in CD362/2 mice would promote
reverse cholesterol transport in vivo but it does not explain the
enhanced efflux of cholesterol that is observed in isolated CD362/2
hepatocytes and macrophages in vitro. The elevated cholesterol/PL
efflux in CD362/2 cells appears due at least in part to enhanced cell
surface ABCA1 re-distribution. ABCA1 is present in the plasma
membrane as well as in subcellular compartments such as late
endosomes and lysosomes[50]. Internalization and recycling of
ABCA1 are integral to cholesterol mobilization, which involves
cholesterol pools in the membrane, the endoplasmic reticulum in
addition to endocytic and lysosomal compartments[28,50]. CD36
may influence ABCA1 recycling directly or via altering distribution
of cholesterol and phospholipids in intracellular pools related
to apoA-I or nascent HDL lipidation. Recent evidence points
to the important role of lipid droplets in distributing various lipids
to membrane-bound intracellular organelles[51,52,53]. CD36 is
among proteins identified on lipid droplets by proteomic studies
[[54] and N Wolins, personal communication] but whether it plays
a role in droplet formation is unknown. In human carotid lesion
samples, CD36 expression positively correlates with adipophilin
(ADRP)[55], a lipid droplet protein that also influences cellular
cholesterol distribution[56] and efflux[57]. ADRP protein levels are
significantly reduced in CD362/2 macrophages (Fig. S3). Thus
CD36 may impact ABCA1 localization and cholesterol efflux via
influencing intracellular lipid partitioning, which would be
consistent with its effect on lipoprotein production in the
intestine[14] and possibly the liver (Fig. 3). ABCA1 trafficking
involves rab proteins[40] and the possibility that these may be
altered in CD362/2 cells will also need to be considered.
Overall the findings both in vivo and in primary cells in vitro
support a negative relationship between CD36 expression and
HDL formation. They provide potential mechanisms for the
associations observed in humans between polymorphisms in the

CD36 gene and plasma HDL[17]. A coding variant that results in
partial CD36 protein deficiency associated with higher HDL levels
and was protective against the metabolic syndrome. Furthermore,
our unpublished findings in humans [Love-Gregory et al] indicate
that monocyte CD36 level is inversely related to plasma HDL.
Thus it is possible that an important influence of CD36 in vivo is on
cholesterol efflux and reverse cholesterol transport. CD36
downregulation may be beneficial for protection from atherosclerotic disease as it would reduce foam cell formation via enhancing
cholesterol efflux in addition to reducing cholesterol uptake by
macrophages.
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